Navigation Links
ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine

IRVINE, Calif., May 08, 2007 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc., today announced results from the preliminary analysis of its U.S. Phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily. The primary endpoints of the study were the assessment of efficacy for bepotastine in treating ocular itching and redness. The preliminary results of the study demonstrate both concentrations were highly statistically significant in the reduction of the first primary endpoint, ocular itching, when dosed twice a day, and in one concentration when dosed once a day. In addition, both concentrations and dosing regimens produced highly statistically significant differences in the rapidity of response and the improvement in total nasal symptoms vs. placebo. In the preliminary evaluation of the second primary endpoint, ocular redness, bepotastine showed a trend toward clinical significance, but did not achieve statistical significance. Several ocular allergy products have been approved by the FDA based on Phase III clinical data demonstrating the achievement of statistical significance and clinical success for one of the primary endpoints, ocular itching or redness.

ISTA plans to complete the Phase II/III study analysis and then discuss the results with the Food and Drug Administration to determine the remaining clinical studies required to confirm ocular safety and efficacy for the submission of an NDA for bepotastine for the treatment of allergic conjunctivitis.

"Bepotastine's multiple mechanisms of action have the potential to provide allergy sufferers with comprehensive protection for the treatment of their ophthalmic and nasal symptoms. We are impressed with the convenient dosing schedule, the rapid onset of action, and clinical efficacy bepotastine exhibited in this study,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/9/2009)...E, N.J., Nov. 9 Par Phar...ounced that it has extended the expiration date an...nnounced "Modified Dutch Auction" tender offer, in...o $65,000,000 aggregate principal amount, or up to...nior Subordinated Convertible Notes due 2010. ,...
(Date:11/9/2009)...., Nov. 9 OriGene Technologies, In...n Sweden has adopted its VERIFY Tagged Antigen(TM)...las program. This program is funded by the Knut an...lore the human proteome systematically using Antib...o-specific antibodies in a high throughput manner ...
(Date:11/9/2009)...v. 9, 2009 Monsanto Comp...ay announced that they have entered into an agreem...Village Research Center located in Chesterfield, M...l acquire the property from Pfizer for $435 millio...o have operations at Chesterfield Village through ...
Breaking Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3The Alpha 1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics Inc 14451 1The Alpha 1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics Inc 14451 2The Alpha 1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics Inc 14451 3The Alpha 1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics Inc 14451 4MedQuist Announces Reseller Agreement With Clario 5448 1MedQuist Announces Reseller Agreement With Clario 5448 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 5446 1FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 5446 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 5446 3
...WN, W.Va., Sept. 5 A team of,researchers at West ... from,India and Pakistan take on the habits of the...tate cancer among male immigrants and breast cance...cer develop due to many reasons, but,environmental...cancers,",said Jame Abraham, M.D., medical directo...
...Roche first in TaqMan(R) real-time PCR testing for...ab, PLEASANTON, Calif., Sept. 4 The U.S. Food & ...OBAS(R) TaqMan(R) HBV Test,the first assay for qua...S.,The test uses Roche,s real-time PCR technology ... a patient,s blood. Doctors may use viral load,tes...
Other Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3
(Date:11/9/2009)...tary Vilsack, Governor Patrick, and Lieutenant Gov...ewswire/ -- In a groundbreaking move for antihunge...) called for all of the state,s hospitals to take ... care. ,, "With 554,000 people in Massachusett...ss conference at UMass Memorial Health Care in Wor...
(Date:11/9/2009)...wswire/ -- The House version of health care reform...hich passed by a vote of 220-215 on Saturday, Nove...s to the tax code and differs in many ways from th...rsion, requiring extensive reconciliation to reach...riefing on the tax provisions of the legislation...
(Date:11/9/2009)...Obama,s promise to not expand abortion ,, Sen...l concerned for poor, elderly ,, WASHINGTON, N...George of Chicago, president of the United States ...r 7 decision of the U.S. House of Representatives ...ing for elective abortions. ,, In a statement ...
(Date:11/9/2009)...qually, study finds, , , MONDAY, Nov. 9...ng drug Plavix (clopidogrel) works about the same ...trials has found. , "After this study, I can sa...en with this very important drug," said Dr. Jeffre... at New York University Langone Medical Center in ...
(Date:11/9/2009)...could boost self-esteem, researchers say , ...hildren are more likely to have handwriting proble...without autism, researchers say. , The new stud...study participants had autism spectrum disorder, b...nge for perceptual reasoning on an IQ test. , T...
Breaking Medicine News(10 mins):Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3Health News:CCH Briefing Details Tax Provisions of House Health Care Bill 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Handwriting Skills May Lag in Kids With Autism 2
... The U.S. Food and Drug Ad...tment for vertigo and dizziness which helps guide ...he U.S. , Calgary, Canada...atment for vertigo] and dizziness which helps guid...
... The latest edition of the...magazine Inc. has made it official -Brightway Insu... property and casualty insurance agency in the cou...ness magazine Inc. has made it official -Brightway...
...ndomized, double-blind, placebo-controlled study c...acy and safety of Nasacort AQ(R) in children wi...ic rhinitis, BRIDGEWATER, N.J., Sept. 23 Sanofi-...-5,years old for the treatment of nasal symptoms a...
...irteenth Trial Conviction for Medicare Fraud Strik...federal jury in Los,Angeles today convicted the ow...Angeles based durable medical equipment (DME) comp...l District of,California Thomas P. O,Brien announc...
...NTA ANA, Calif., Sept. 22 Grubb & Ellis,Healthcar...lahoma City,Medical Portfolio, comprising two medi...5401 and 5701 N. Portland, the buildings are situa...ttractive additions to the Grubb,& Ellis Healthcar...
...mantic search leader hakia will expand its credibi...tent, WASHINGTON, Sept. 22 Semantic search engin... and information professionals to,participate in a...ical searches to guide users towards credible Web,...
Other Medicine News:Health News:Clearwater's Canadian at-Home Dizziness Treatment Device Cleared by FDA 2Health News:Brightway Insurance Earns a Spot on the INC 5000 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 3Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 4Health News:Los Angeles Jury Convicts Defendant of Fraud Involving More Than $1.1 Million in False Billing to Medicare 2Health News:Los Angeles Jury Convicts Defendant of Fraud Involving More Than $1.1 Million in False Billing to Medicare 3Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 2Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 3Health News:hakia Issues Open Call to Librarians and Information Professionals: Help Us Guide Web Searchers to Credible Web Sites 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: